·KMV002 (IPT-PAP, IND-ready): A first-in-class immune-priming therapeutic for metastatic castration-resistant prostate cancer (mCRPC), engineered to convert prostate tumors from immune-cold to immune-responsive and enhance the activity of checkpoint inhibitors, AR-targeted agents, radioligands, and emerging modalities.

KMV002 is an investigational therapeutic cancer vaccine currently under clinical development and has not been approved by any regulatory authority.

At this time, ChimiVac does not offer expanded access (also known as compassionate use) to KMV002 outside of authorized clinical trials.

This policy is based on several considerations, including:

·Limited clinical safety information currently available;

·The need to complete ongoing clinical development;

·Limited manufacturing supply;

·The importance of ensuring patient access through controlled clinical studies.

·ChimiVac periodically reviews this policy as clinical development progresses.

Physicians seeking additional information may contact:

Medical Affairs

ChimiVac, Inc.

Email: medical@chimivac.com

Last Updated: October 2026

·SN2001 (IPT-HBV, Phase I): A multi-epitope immune-restoring therapeutic for chronic HBV designed to re-establish functional antiviral immunity in patient populations with profound immune exhaustion.